Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716764 | 1.00 | HTT (0.41) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL1934826 | 1.00 | HTT (0.41) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL24025165 | 0.92 | CA1 (0.44) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL19725793 | 0.88 | TDP1 (0.40) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL15366759 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL15366764 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL15939262 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL15366761 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL19868233 | 0.83 | CA1 (0.42) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL3301617 | 0.83 | HTT (0.37) | HTTTDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355138-A1 | AMINOTHIAZINIES AND THEIR USE AS BACE1 INHIBITORS | LILLY CO ELI (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3497105-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018031334-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-02-15 | — | — | WO | disclosed |
| EP-2935282-A1 | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | Pfizer Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2332943-B1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014097038-A1 | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2332943-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355138-A1 | AMINOTHIAZINIES AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | HTT 373/4885TDP1 355/4885CA1 1624/4885 |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | HTT 267/4885TDP1 1386/4885CA1 866/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | HTT 231/4885TDP1 2865/4885CA1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.